Blue light-filtering IOL significantly reduces driving glare disability

Article

Using blue light-filtering IOLs, as opposed to UV-only filtering non-toric IOLs, produces a significantly greater reduction in glare disability when driving.

Using blue light-filtering IOLs, as opposed to UV-only filtering non-toric IOLs, produces a significantly greater reduction in glare disability when driving, reveals an investigation in the Journal of Cataract and Refractive Surgery.

Dr Rob Gray and his team, Department of Applied Psychology, Arizona State University, Mesa, Arizona, USA, conducted a comparative case series on patients wearing a blue light-filtering IOL (the test IOL) or an ultraviolet (UV)-only filtering non-toric IOL (the control IOL).

Patients were asked to perform left-turn manoeuvres in a driving simulator while wearing best spherocylindrical correction. Time to collision minus the time taken to turn at a junction into oncoming traffic was used to define the safety margin. The same process was repeated but during daytime driving conditions with a glare source.

The test IOL was administered to 18 patients and the control IOL was given to 15 patients. Safety margins were significantly greater in patients with the test IOL in situations where glare was present.

Patients with the test IOL presented with a significantly lower glare susceptibility than the control patients. The blue light-filtering IOL enabled drivers to turn left in situations where glare is present.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.